RD-129

N/A

Report date: 2024/04/17 14:32:48

Base Information

Drug NameRD-129
Drug Alias NameRD129
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Iaso Biotherapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Iaso Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A